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ABSTRACT
Objectives: Areas with high HIV-incidence rates compared
to the developed world may beneﬁt from additional testing in
blood banks and may show more favorable cost-effectiveness
ratios. We evaluated the cost-effectiveness of adding p24
antigen, mini pool nucleic acid ampliﬁcation testing (MP-
NAT), or individual donation NAT (ID-NAT) to the HIV-
antibody screening at the Korle Bu Teaching Hospital (Accra,
Ghana), where currently only HIV-antibody screening is
undertaken.
Methods: The residual risk of HIV transmission was derived
from blood donations to the blood bank of the Korle Bu
Teaching Hospital in 2004. Remaining life expectancies of
patients receiving blood transfusion were estimated using
the World Health Organization life expectancies. Cost-
effectiveness ratios for adding the tests to HIV-antibody
screening only were determined using a decision tree model
and a Markov model for HIV.
Results: The prevalence of HIV was estimated at 1.51% in
18,714 donations during 2004. The incremental cost per
disability-adjusted life-year (DALY) averted was US$1237
for p24 antigen, US$3142 for MP-NAT and US$7695 com-
pared to the next least expensive strategy. HIV-antibody
screening itself was cost-saving compared to no screening at
all, gaining US$73.85 and averting 0.86 DALY per transfused
patient. Up to a willingness-to-pay of US$2736 per DALY
averted, HIV-antibody screening without additional testing
was the most cost-effective strategy. Over a willingness-to-
pay of US$11,828 per DALY averted, ID-NAT was signiﬁ-
cantly more cost-effective than the other strategies.
Conclusions: Adding p24 antigen, MP-NAT, or ID-NAT to
the current antibody screening cannot be regarded as a cost-
effective health-care intervention for Ghana.
Keywords: blood transfusion, cost-effectiveness, developing
countries, NAT, screening.
Introduction
As with many other countries in the same sub-Saharan
West-African region, Ghana currently faces a signiﬁ-
cant percentage of the population living with HIV/
AIDS, recently estimated at 3.1% [1]. The epidemic
in Ghana is mainly driven by heterosexual contact,
responsible for approximately 80% of HIV transmis-
sions. Additionally, mother-to-child transmission
accounts for an additional 15% [2]. Contribution of
blood transfusion as a mode to transmit HIV infection
is currently not reported ofﬁcially. Nevertheless, HIV
transmission has recently been estimated in the litera-
ture at one per 2578 donations given, despite routine
HIV-antibody screening for donations in Ghana [3].
This compares unfavorably to the developed world,
where the risk of HIV transmission after serological
screening is estimated below one per million dona-
tions, which has also been mainly achieved through
HIV-antibody screening [3,4].
Yet, in the developed world screening techniques
in addition to HIV-antibody testing invariably show
low returns at high costs resulting in unfavorable cost-
effectiveness ratios. Reasons for this include the low
baseline and remaining undetected HIV incidence in
blood donors, the likelihood that donors with high risk
of HIV infection are actively deferred, donors being
adequately followed, and donation being based on a
voluntary nonremunerated system [4,5]. In many
developing countries, including Ghana, blood banking
mainly relies on donors replacing the units transfused
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to a family member, relative, or friend and active defer-
ral is generally not pursued. Such replacement donors
are prone to having a higher HIV prevalence [6].
Moreover, follow-up of replacement donors and regis-
tration of infective status is practically impossible
because of poor donor registration that severely
restricting traceability.
The population of blood transfusion recipients in
sub-Saharan Africa is on average younger than blood
transfusion recipients in the developed world, as young
patients with malaria and iron deﬁciency-related pedi-
atric anemia represent a large share in the patient
population. Blood-transfusion HIV transmission may
result in further productivity losses in sub-Saharan
Africa, on top of substantial productivity losses for
other reasons related to HIV/AIDS status.
In the presence of routine antibody screening, HIV
transmission through blood transfusion can occur if
antibody testing is performed during the window
period of antibody testing. This period reﬂects the time
between development of infectious viremia in the HIV-
infected person (in this case the donor) and antibody
screening reactivity. Nucleic acid ampliﬁcation testing
(NAT) and p24-antigen screening techniques are able
to reduce the window period because these are direct
tests on the virus and therefore have reactivity on the
viral particles rather than the antibodies that present
later [7]. As the virus may become undetectable in later
stages of infection, direct tests are always performed
alongside antibody screening. Weighting the costs of
adding testing techniques to the health gain and mon-
etary beneﬁts of reduced HIV infections––i.e., reduced
costs for Highly Active AntiRetroviral Therapy
(HAART) and reduction of productivity loss—is
crucial. This may be particularly important for
resource-poor countries.
We designed this study to evaluate the cost-
effectiveness of adding p24-antigen screening, mini
pool NAT (MP-NAT), or individual donation NAT
(ID-NAT) to the HIV-antibody screening currently in
place in Ghana. The HIV-antibody test in Ghana is
performed post donation, on the donated units. Addi-
tionally, we analyzed the cost-effectiveness of the
current routine antibody screening, compared to a
hypothetical strategy of no HIV-screening of blood
donations in Ghana.
Data, Methods, and Model
General Model Outline
Cost-effectiveness of p24-antigen testing, MP-NAT,
ID-NAT, HIV-antibody screening, and no screening
for HIV (“do nothing” option) was evaluated from the
societal perspective. In particular, both direct medical
and indirect production loss costs were included. We
estimated incremental cost-effectiveness ratios (ICERs)
by relating the additional costs of a screening strategy
to the additional health gains of that same strategy, as
compared to the next least expensive screening strat-
egy. Screening strategies that cost more and yield less
health gains than another screening strategy (i.e., were
dominated) were excluded. Additionally, the relative
cost-effectiveness ratio (CER) was estimated relating
the additional costs and health gains of a screening
strategy as compared to HIV-antibody screening.
Because decision-makers in blood banking in Africa
are interested in the relative value of a new test in
addition to HIV-antibody screening, we report the
relative risk reduction compared to HIV-antibody
screening and the associated CER. Estimated ICERs
and CERs were compared to the per capita Gross
National Income (GNI) of Ghana. According to the
World Health Organization (WHO) guidelines, strate-
gies with an (I)CER below the per capita GNI are
regarded as cost-effective, whereas strategies with an
(I)CER more than three times the per capita GNI are
considered not cost-effective [8–10]. Health gains were
expressed in disability-adjusted life-years (DALYs)
averted. DALYs averted as the outcomes captures both
differences in premature death as well as morbidity
achieved by averting transfusion-transmitted HIV for
each speciﬁc screening strategy compared to another.
DALYs were chosen to reﬂect burden of disease rather
than quality-adjusted life-years to be in line with other
analyses assessing cost-effectiveness of HIV prevention
in sub-Saharan Africa, that all report ratios per DALY
averted [11,12]. DALYs associated with each screening
strategy were determined by multiplying the residual
risk of HIV transmission (because of the window
period) for the speciﬁc screening strategy with the
DALYs related to transfusion-acquired HIV. DALYs
were discounted at 3% and weighted for age in the
base case; an evaluation without age-weighting was
also performed [13]. Costs per screening strategy were
estimated by adding costs of screening, health-care
costs of transfusion-acquired HIV, and production
losses. Future costs were also discounted at 3%.
The robustness of the model was investigated by
varying key parameters in sensitivity analysis. Sce-
nario analyses were used to explore future changes in
epidemiologic parameters, such as HIV prevalence in
blood donors and availability of HAART for infected
patients. In a threshold analysis test costs were deter-
mined where screening strategies yielded a CER rela-
tive to HIV-antibody screening that was equal to the
GNI per capita and three times the GNI per capita
[9,10,14]. Uncertainty was evaluated by second-order
Monte Carlo simulation (10,000 runs) using prob-
ability distributions derived from data gathered on
screening methods, blood donors, and blood trans-
fusion recipients. Where applicable, uncertainty
intervals (UIs) are presented as 2.5% and 97.5%
percentiles.
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Acceptability curves were constructed to evaluate
the probability of accepting a screening strategy for
different levels of willingness-to-pay (WTP) for a
DALY averted, using the net monetary beneﬁt frame-
work [15]. The net monetary beneﬁt (NMB) at a given
WTP for a DALY averted is deﬁned as the dif-
ference between the respective WTP multiplied by the
DALYs averted for a given strategy and the costs of
that strategy:
NMB DALYs C= × −λ
with l reﬂecting the WTP and C costs. Analyses to
derive NMBs were also based on second-order Monte
Carlo simulation. The proportion of the 10,000 runs
that a speciﬁc screening strategy has the highest NMB
represents the estimated probability of that strategy
being cost-effective. Subsequently, the probability to be
cost-effective is plotted against the WTP, resulting
in an acceptability curve [16]. We assumed that a
decision-maker would accept the more expensive
screening strategy if it has been shown to be signiﬁ-
cantly (at 5% level) more cost-effective than a less
expensive strategy.
Residual Risk of HIV Transmission
The residual risk of HIV-infected transfusion despite
screening was determined with an adapted version of
the window-phase model [17]. Pivotal in the window-
phase model is incidence of HIV in blood donors after
follow. Because blood donors in Ghana are not fol-
lowed, the incidence of HIV among blood donors
cannot be determined. We therefore used HIV preva-
lence as next best approach for estimating the residual
risk of HIV transmission. The risk of HIV transmission
after screening was deﬁned as a fraction with the
window period for the speciﬁc screening strategy in the
numerator and the mean duration of asymptomatic
HIV infection (WHO stages 1 and 2) multiplied with
the prevalence of HIV among blood donors in the
denominator. Therefore, we implicitly assumed that
only donors without clinical signs of HIV infection
would be able to donate without prior deferral by
blood bank employees. Within the total period from
HIV infection to the development of AIDS (WHO
stages 1–3; estimated at 7.89 years), the duration of
HIV stages without apparent clinical signs was esti-
mated at 5.04 years [18,19].
HIV prevalence was retrospectively determined at
1.51% fromHIV-antibody screening (Vironostika Uni-
Form II plus O, Boxtel, The Netherlands) of 18,714
donations to the National Blood Transfusion Service
(Korle Bu Teaching Hospital, Accra, Ghana) in 2004.
Initial positivity to HIV-antibody screening was found
in 579 donations, and repeat reactivity was found for
282 donations. Replacement donations were 66% of
the total number of donations.
Patient Population, HIV, AIDS, and DALYs
The health effects of transfusion-transmitted HIV
infection were modeled using prospective data on 193
transfused patients at the Korle Bu Teaching Hospital
(Accra, Ghana) during February 2003 (patient study).
Mainly relatively young patients received blood trans-
fusion. In particular, 42% of the patients receiving a
blood transfusion (35 female and 46 male) were
younger than 12 years and 19% (16 female and 21
male) were younger than 2 years. The average age of
the blood transfusion recipient was 23.4 years, and
124 of the included patients were female. Malaria
and/or related complications were the predominant
indications for blood transfusion in patients under
12 years (69%). Blood transfusions in older patients
were mainly used for gynecologic and obstetric condi-
tions (37%), such as abortion (15%). To control for
seasonal variations in the blood transfusion recipient
population, the proportions of patients under 12 years
old and above 12 years in the patient study were
adjusted using the proportions of these age groups
identiﬁed from the blood bank issue records from
2002 to 2004 (6734 patients below 12 years and
13,605 above 12 years). These adjusted percentages
are listed in Table 1 and were conceived as probabili-
ties in the model.
Because whole blood was the predominant blood
product transfused, one donation was assumed to
yield one unit for transfusion. Patients received on
average 1.66 units of blood per transfusion. Patients
less than 2 years old received on average 0.51 units,
while patients of 2 years up to 12 years and patients
of 12 years or older received 1.0 and 2.3 units,
respectively. In the model, any HIV-infected unit
transfused—either fully or partly—was assumed to
result in HIV transmission to the recipient. Addition-
ally, it was assumed that for each HIV-infected blood
transfusion recipient there would be 0.84 secondary
transmissions through heterosexual contact, which is
in line with estimates of the so-called basic reproduc-
tion rate (reﬂecting the multiplication of the number
of heterosexual partners, transmission probability per
partner, and duration of the HIV stages) [20–22]. Sec-
ondary transmissions through other routes were not
included [23].
As part of the estimation of DALYs, years of life lost
per patient due to HIV infection were determined as
the difference between the patients’ remaining life
expectancy without HIV infection and the life expect-
ancy with HIV infection. Age- and sex-speciﬁc remain-
ing life expectancies were taken from WHO and
applied to patients receiving blood transfusions [24].
The health effects of HIV transmission were not
included for patients who died in hospital because of
the underlying disease. Long-term excess mortality for
blood transfusion recipients was not included in the
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model as this is only described for the developed
world, where patients transfused are older and suffer
from other underlying diseases that often severely
affect life expectancy [5,25,26].
Years lived with disability were calculated by mul-
tiplying the time in HIV stages or AIDS with the
appropriate disability weights [13]. Using Markov
modeling, the duration of HIV stages 1 to 3 was esti-
mated at 7.89 years, and the duration of the AIDS
stage was estimated at 0.5 years [19]. Extension of
HIV stage 3 due to longevity by HAART was included
with a baseline assumption of 5% availability of anti-
viral drugs, reﬂecting the current scarce availability
in Ghana [1,27,28]. HAART was estimated to yield an
additional 12 life-years in the baseline, with 9 and
24 years of life extensions explored in the sensitivity
analysis [29–31].
Finally, DALYs associated with HIV infection—
and potentially averted through improved testing
strategies—were calculated by summing years of life
lost and years lived with disability.
Screening Costs, Health-Care Costs, and
Productivity Losses
All costs were expressed in 2004 price levels. Screening
costs were estimated by multiplying the cost of screen-
ing per donation with the number of units transfused
per patient. Screening costs were obtained from litera-
ture and subjected to sensitivity analysis [3,5]. Costs of
HAART were calculated using ofﬁcial Ghanaian drug
prices and a costing study for health-care costs associ-
ated with the provision of HAART [18]. All infected
patients received basic care for sequelae of HIV infec-
tion [17]. Productivity losses were estimated by cumu-
lating annual earnings weighted for age and corrected
for unemployment, for the expected survival from the
moment of HIV infection, see Table 1 [32].
Table 1 Model variables, probability distributions, and sources
Model variable Parameters and probability distribution Source
Test characteristics
Window HIV-Ab (standard) Normal; mean: 20.3 days; SE: 1.6 [4,5]
Window p24 antigen & HIV-Ab Normal; mean: 15 days; SE: 1.3 [4,5]
Window MP-NAT & HIV-Ab Normal; mean: 9 days; SE: 0.6 [4,5]
Window ID-NAT & HIV-Ab Normal; mean: 5.6 days; SE: 0.4 [4,5]
Costs of HIV-Ab (standard) US$5 [4,5]
Additional costs of p24 antigen US$2 [4,5]
Additional costs of MP-NAT US$7.5 [4,5]
Additional costs of ID-NAT US$15 [4,5]
Patients and disease
Age of patients: <2 years Normal; mean: 0.89; SE: 0.087; 37 patients
Percentage of units transfused: 8.9%
Patient study & NBTS
Age of patients: 2–12 years Normal; mean: 4.27; SE: 0.34; 44 patients
Percentage of units transfused: 12.6%
Patient study & NBTS
Age of patients:12 years Normal; mean: 38.5; SE: 1.63; 111 patients
Percentage of units transfused: 78.7%
Patient study & NBTS
Number of transfusions per donation 1.66 Patient study & NBTS
In hospital mortality, patients <2 years 10.8% Patient study
In hospital mortality, patients 2–12 years 4.5% Patient study
In hospital mortality, patients 12 years 7.3% Patient study
Duration of HIV stages (patients <2 years) Normal; mean: 2.41 years; SE: 0.143 Markov model
Duration of HIV stages (patients 2 years) Normal; mean: 7.89 years; SE: 0.280 Markov model
Disability weight HIV stages (<12 years) 0.123 [13]
Disability weight HIV stages (12 years) 0.136 [13]
Duration of AIDS stage (all patients) Normal; mean: 0.51 years; SE: 0.035 Markov model
Disability weight AIDS stage (all patients) 0.505 [13]
Coverage antiretroviral therapy 5% (s.a.: 1.25–100%) [1]
HIV stage 3 extension by HAART Uniform; 11–13 years extension
(s.a.: 8–10 and 23–25 years extension)
[29,30]
R0 0.84 [21–23]
Annual costs of basic care for HIV/AIDS US$32.54 [18]
Annual costs of antiretroviral therapy US$1087.67 (s.a.: US$380–2200) [18]
Productivity losses
Unemployment 20% [32,39]
Age adjustment for earnings 0–5 years = 0 [32]
6–15 years = 0.15
16–50 years = 1
51–65 years = 0.85
66 years = 0.25
Average annual earnings US$127 [32]
Test costs are expressed per donation.All costs in 2004 US$.
Ab, antibody; HAART, Highly Active AntiRetroviral Therapy; ID-NAT, individual donation nucleic acid ampliﬁcation testing; MP-NAT, mini pool nucleic acid ampliﬁcation testing;
NBTS, National Blood Transfusion Service (Korle Bu Teaching Hospital,Accra, Ghana); R0, basic reproduction rate; s.a., sensitivity analysis; SE, standard error.
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Results
Base-Case Analysis
The residual risk of HIV transmission was estimated
at 2.76 per 10,000 donated units for HIV-antibody
screening. Implementing p24 antigen (additional cost
per donation: US$2), MP-NAT (additional cost per
donation: US$7.5), or ID-NAT (additional cost per
donation: US$20) in addition to HIV-antibody screen-
ing would lower HIV-transmission risks to 2.04, 1.22,
and 0.76 per 10,000 units donated, respectively. When
added to HIV-antibody screening, ID-NAT averted
most HIV transmissions and DALYs, followed by
MP-NAT and p24-antigen screening (see Table 2).
HIV-antibody testing compared to no screening
showed the highest reduction in transmission of HIV
and averted the most DALYs. The incremental net
costs of performing p24-antigen screening, MP-NAT,
or ID-NAT alongside HIV-antibody testing were
highest for ID-NAT followed by MP-NAT and p24-
antigen screening (see Fig. 1). HIV-antibody screening
results in an estimated cost-saving of US$444,901 and
5159 DALYs averted per 10,000 donations compared
to no screening, i.e., antibody screening dominates no
screening. This translates to US$73.85 cost-savings
and 0.86 DALYs averted per transfused patient. The
ICER of p24-antigen testing, MP-NAT, and ID-NAT in
addition to HIV-antibody screening was least favor-
able for ID-NAT, followed by MP-NAT and p24-
antigen screening, respectively (see Fig. 1). The same
rank order was found for the relative CER for p24-
antigen testing, MP-NAT, and ID-NAT compared to
HIV-antibody screening (see Table 2).
The reduced production losses and health-care
savings from expanded testing are estimated to be
US$1440 (95% UI: 390–2544), US$3069 (95% UI:
2191–4015), and US$3993 (95% UI: 3119–4918) per
10,000 donations for p24 antigen, MP-NAT, and
ID-NAT relative to HIV-antibody screening, respec-
tively. Compared to no screening, HIV-antibody
screening is estimated to save US$494,901 per 10,000
donations (95% UI: 471,412–519,992) in reduced
production losses and health-care costs. Per transfused
patient this amounts to US$82.15.
If accepting only the screening strategy that demon-
strates signiﬁcantly greater cost-effectiveness (at the
5% level), the acceptability curve indicates that
up to a WTP of US$2736 per averted DALY HIV-
antibody screening is the preferred strategy. At a per
capita GNI of US$380 in Ghana, antibody screening
Table 2 HIV infections averted and relative cost-effectiveness ratios of the base case (per 10,000 donations)
Strategy
HIV infections averted
UI [95%]
DALYs averted
UI [95%]
Net costs (US$)
UI [95%]
Cost-effectiveness (US$/DALY)
UI [95%]
Base case
Ab vs. no screening 241 [240.6 to 241.5] 5159 [4876 to 5448] -444,901 [-469,567 to -420,972] -86 [-79.84 to -93.29]
p24 vs.Ab screening 0.70 [0.17 to 1.23] 15.0 [3.74 to 26.34] 18,560 [17,484 to 19,635] 1237 [652 to 4568]
MP-NAT vs.Ab screening 1.50 [1.05 to 1.94] 32.0 [22.55 to 41.75] 71,931 [70,997 to 72,832] 2248 [1701 to 3228]
ID-NAT vs.Ab screening 1.95 [1.51 to 2.37] 41.6 [32.33 to 51.27] 146,007 [145,086 to 146,879] 3508 [2830 to 4543]
All costs in 2004 US$.
Ab, antibody; DALY, disability-adjusted life-year; ID-NAT, individual donation nucleic acid ampliﬁcation testing; MP-NAT, mini pool nucleic acid ampliﬁcation testing; UI, uncertainty
interval.
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Figure 1 Total costs (cost of screening, health
care, and productivity loss) of the screening
strategies and averted loss of life and health
(disability-adjusted life-years [DALYs]) per
10,000 donations. All costs in 2004 US$. No
screening for HIV is not displayed, because this
strategy is clearly dominated: 0 DALYs were
averted and total costs were US$500,415. Rela-
tive to no screening, HIV-antibody (Ab) screen-
ing saved US$444,901 in total costs. ICER,
incremental cost-effectiveness ratio; ID-NAT,
individual donation nucleic acid ampliﬁcation
testing; MP-NAT, mini pool nucleic acid ampliﬁ-
cation testing.
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was the preferred strategy up to the three-times-
per-capita GNI threshold of US$1140 (see Fig. 2).
ID-NAT in addition to HIV-antibody screening was
considered to be the most cost-effective approach at a
WTP of US$11,828 per averted DALY and above.
Between both switching points no clear preference
existed for adding p24 antigen or MP-NAT to HIV-
antibody screening. The probability of accepting a no
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Figure 2 Acceptability curves for the base case and selected scenarios of expanded HIV-screening. More expensive screening techniques are accepted
if signiﬁcantly cost-effective (at 5% level) compared to the current strategy (accepted strategy above accolade).Ab-screening,HIV-antibody screening (—–);
p24-screening, p24-antigen screening (– – –); MP-NAT, mini pool nucleic acid ampliﬁcation testing (– - –); ID-NAT, individual donation nucleic acid
ampliﬁcation testing (- - -); HAART, Highly Active AntiRetroviral Therapy. Vertical lines: —– represents the switching points where a more expensive
screening strategy becomes signiﬁcantly more cost-effective (at the conventional 5% level); .... and ----- represent the per capita Gross National Income
(GNI) (US$380) and three times the per capita GNI (US$1140) of Ghana as indicated potential thresholds by the World Health Organization.
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screening strategy for HIV being cost-effective was
zero (this is not shown in the acceptability curves as it
coincides with x-axis).
For a decision-maker choosing the most cost-
effective strategy, HIV-antibody screening alone would
be the preferred strategy up to a WTP of US$1245 per
DALY averted. p24-antigen screening in addition to
HIV-antibody screening represents the most cost-
effective screening strategy from a WTP of US$1246
up to 3143 per averted DALY (although not signiﬁ-
cantly so, as mentioned above). MP-NAT was the most
cost-effective screening technique for a WTP between
US$3144 up to 7698 per DALY averted, and over this
range ID-NAT added to HIV-antibody screening was
the most cost-effective strategy.
Scenario and Conventional Sensitivity Analysis
Expected changes in the availability of HAART and
the impact of changing HIV prevalence among blood
donors were evaluated in a worst and best case sce-
nario. In particular, within the “3 by 5 initiative”
framework, it is envisioned that HAART will be pro-
vided to all HIV-infected patients fulﬁlling the require-
ments for CD4 counts and WHO stage. In 2005, 3500
out of approximately 71,000 patients eligible for treat-
ment were provided with HAART in Ghana (5%), but
with 29,000 patients (41% of patients eligible for
treatment) targeted to receive HAART by the end of
2005 [1]. Compared to other African countries, the
prevalence of HIV has grown modestly. Nevertheless,
there is no evidence to suggest that prevalence is
declining or even reaches a plateau because of the
preventive measures being undertaken nationally.
The scenario with a HIV prevalence of 3% among
blood donors and 100% availability of HAART to
eligible infected transfusion recipients showed lower
CERs compared to the base case for adding p24
antigen, MP-NAT, or ID-NAT to HIV-antibody screen-
ing (Fig. 3). Up to a WTP over US$979 per DALY
averted, HIV-antibody screening is the preferred strat-
egy; whereas more than US$6614 per DALY averted,
ID-NAT in addition to HIV-antibody screening is sig-
niﬁcantly more cost-effective (see Fig. 2).
In a scenario exploring an HIV prevalence of
1.51% (base case) among blood donors and 100%
of eligible HIV-infected patients having access to
0 4000 8000 12000
CER (US$/DALY averted)
ID-NAT (without age-weighting)
MP-NAT (without age-weighting)
p24 (without age-weighting)
HIV-Ab (without age-weighting)
ID-NAT (HAART US$2,200 - 380)*
MP-NAT (HAART US$2,200 - 380)*
p24 (HAART US$2,200 - 380)*
HIV-Ab (HAART US$2,200 - 380)*
ID-NAT (R0 1.68 - 0.42)
MP-NAT (R0 1.68 - 0.42)
p24 (R0 1.68 - 0.42)
HIV-Ab (R0 1.68 - 0.42)
.
ID-NAT (0.75% HIV & 2.5% HAART)
MP-NAT (0.75% HIV & 2.5% HAART)
p24 (0.75% HIV & 2.5% HAART)
HIV-Ab (0.75% HIV & 2.5% HAART)
ID-NAT (0.75% HIV & 100% HAART)
MP-NAT (0.75% HIV & 100% HAART)
p24 (0.75% HIV & 100% HAART)
HIV-Ab (0.75% HIV & 100% HAART)
ID-NAT (100% HAART)
MP-NAT (100% HAART)
p24 (100% HAART)
HIV-Ab (100% HAART)
ID-NAT (3% HIV & 100% HAART)
MP-NAT (3% HIV & 100% HAART)
p24 (3% HIV & 100% HAART)
HIV-Ab (3% HIV % 100% HAART)
ID-NAT (base case)
MP-NAT (base case)
p24 (base case)
HIV-Ab (base case)
Sensitivity analysis 
Base case & scenario analysis 
Figure 3 Cost-effectiveness ratio (CER) ranges and mean (diamond) of the base case, scenario, and sensitivity analysis. Error bars represent the 95%
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HAART, lower CERs were also found for expanding
HIV screening of blood donors, except for ID-NAT
(see Fig. 3). The rank order did not change compared
to the base case. HIV-antibody screening alone was the
preferred strategy up to a WTP of US$2739 per DALY
averted HIV and for a WTP over US$14,061 per
DALY averted adding ID-NAT was signiﬁcantly the
most cost-effective option (see Fig. 2). For a HIV
prevalence in donors of only 0.75% and with only
2.5% of the patients having access to HAART, the
CERs for extended testing approximately doubled
compared to the base case. Also, cutoff points for
cost-effectiveness were much higher at US$5622 and
US$23,903 per DALY averted for antibody screening
and ID-NAT, respectively.
The estimated relative CERs were very sensitive
to changes in costs per test. Figure 4 illustrates this
for plausible ranges of the total costs per screening
strategy. Within the cost range explored, the CER for
ID-NAT relative to HIV-antibody screening was
always well more than three times the GNI per capita.
The CER for MP-NAT relative to HIV-antibody
screening fell less than three times the GNI per capita
only in the lower part of the cost range.
Threshold analyses on test costs revealed that
highest test costs would be accepted for the most effec-
tive test strategy of ID-NAT, whereas acceptable extra
test costs were the lowest for the least effective strat-
egy. ID-NAT became cost-saving at total costs per
donation of US$5.39 (including costs for antibody
screening), followed by MP-NAT and p24 total test
costs at US$5.30 and US$5.14, respectively. At thresh-
old of the GNI per capita level per DALY averted, the
total test costs could increase up to US$6.98,
US$6.52, and US$5.71 for the three strategies, respec-
tively. If the WHO guidelines and World Bank recom-
mendations were followed and meaning that the
strategies cannot be regarded as cost-effective if the
relative CER increases more than three times the GNI
per capita, the respective thresholds for the total
screening costs were US$10.14, US$8.95, and
US$6.85 per donation for ID-NAT, MP-NAT, and
p24-antigen screening, respectively.
In the base case, it was assumed that each person
infected with HIV by blood transfusion would infect
0.84 other persons by heterosexual intercourse.
Halving and doubling this estimate has a large effect
on the CERs (Fig. 3). Nevertheless, the rank order
remains the same compared to the base case. The CER
of p24-antigen screening relative to HIV-antibody
screening would fall less than three times the GNI per
capita at twice the base-case value for this secondary
transmission. The outcomes of the model are robust to
variations in accessibility to HAART and costs and
health gains of HAART: varying parameters separately
has little impact (<5%) on the cost-effectiveness of
expanded HIV-screening strategies. At high levels of
accessibility to HAART for eligible patients (100%),
the cost of HAART has an impact on the results
(Fig. 3). Increasing the cost of HAART results in lower
CERs for a strategy of expanding HIV-antibody
screening; the rank order remains the same.
Performing DALY estimation without age-
weighting lowered the health gains associated with
extended screening; the DALYs averted per 10,000
donations for p24-antigen screening, MP-NAT, and
ID-NAT were 11.7, 24.9, and 32.3, respectively. The
corresponding CERs were US$1592, US$2894, and
US$4515 per DALY averted for p24 antigen, MP-
NAT, and ID-NAT relative to HIV-antibody screening,
respectively. Antibody screening averted 4008 DALYs
and remained cost-saving compared to no screening,
still dominating the no screening strategy.
Discussion
We investigated the cost-effectiveness of screening
blood donations for HIV in Accra (Ghana) using a
model comprising country- and patient-population-
speciﬁc survival, blood-product utilization, indirect
and direct cost data. The current HIV-antibody screen-
ing strategy was found to save costs and avert mor-
bidity and mortality compared to no screening (domi-
nant). Also, base-case ICERs of screening strategies
added to HIV-antibody screening were all well more
than three times the GNI per capita for Ghana
(US$1140). Therefore, adding screening techniques
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Figure 4 Sensitivity of the relative cost-effectiveness ratio (CER) to
changes of additional screening costs per donation (above HIV-antibody
screening costs). Only plausible ranges are plotted for the additional
screening costs. p24-antigen screening (– – –), mini pool nucleic acid
ampliﬁcation testing (MP-NAT; – - –), and individual donation nucleic acid
ampliﬁcation testing (ID-NAT; - - -) were compared to HIV-antibody
screening.The base case is represented by (); ---- and –– –– –– represent
the Gross National Income (GNI) (US$380) and three times the GNI
(US$1140) of Ghana.
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cannot be regarded as cost-effective based on this
threshold criteria that has been suggested by both the
WHO and World Bank. Moreover, no other screening
strategy was shown to be signiﬁcantly more cost-
effective up to the threshold of three times the Ghana-
ian GNI per capita. In scenario analysis, antibody
screening remained signiﬁcantly more cost-effective
even beyond three times the GNI per capita threshold.
If a decision-maker accepts the strategy which has
the highest probability to be cost-effective (without
requiring this to be statistically signiﬁcantly so),
HIV-antibody screening would still remain the pre-
ferred screening strategy up to three times the GNI
per capita. Adding either p24-antigen screening or
MP-NAT was signiﬁcantly more cost-effective than
antibody screening alone at an HIV prevalence of 3%
and an assumption of full access to HAART. No clear
distinction could be made between p24-antigen screen-
ing and MP-NAT as separately neither were signiﬁ-
cantly more cost-effective. Addition of ID-NAT to
HIV-antibody screening would only be undertaken if
Ghanaian decision-makers would be willing to pay
US$11,828 per DALY averted, which is more than 10
times the GNI per capita for Ghana.
In the last decade, several measures have been under-
taken to attempt to alter the course of the HIV/AIDS
epidemic in Ghana and further activities are planned in
the future. The implementation of programs to induce
(sexual) behavioral changes, reduce mother-to-child
transmission, and increase blood transfusion safety
might curb the HIV-epidemic, and thereby inﬂuence the
cost-effectiveness of expanded HIV screening. ICERs
for HIV screening are fourfold to ﬁvefold lower (more
favorable) for doubling compared to halving base-case
HIV prevalence. Also, the WTP for adding tests to
HIV-antibody screening is fourfold lower for high com-
pared to low HIV prevalence.
Clearly, varying test costs has a profound impact
on the cost-effectiveness. Lowering test costs in the
model would give considerable more favorable cost-
effectiveness of adding tests to HIV-antibody screen-
ing. Also, through price reductions for HAART,
alongside the expected progressive implementation of
accessibility to HAART for eligible patients consider-
able better cost-effectiveness may be achieved for
adding tests. Nevertheless, variations in the costs of
HAART alone had hardly any impact on the CERs in
the base case (with low accessibility at 5% only).
Since age-weighting in the DALY calculation is con-
troversial [33], we also presented results without age-
weighting. Evaluations without age-weighting yielded
higher, more unfavorable cost-effectiveness ratios. If
through education and behavior change the number
of secondary infections could be decreased in the
future, this would lead to less favorable CERs for
adding screening tests to the current antibody screen-
ing. In our analysis, only secondary infections caused
by heterosexual sexual contact were included. This
means that we underestimate the attractiveness of
expanded screening as, for example, contributions of
unsafe injections and vertical transmissions will
further add to secondary cases. Only p24-antigen
screening, however, falls below three times the GNI
per capita at twice the base-case value for the number
of secondary transmissions per infected blood trans-
fusion recipient.
One limitation of our evaluation is the determina-
tion of the residual risk of HIV transmission by using
the HIV prevalence instead of the preferred HIV-
incidence window-phase approach or the application
of a de-tuned assay [17,34]. Nevertheless, our esti-
mated residual risk may be a good approximation, as
the risk of 2.76 per 10,000 donated units after HIV-
antibody screening in the present study falls well
within the range from a previously reported direct
determination. In this study, performed in Kumasi
(Ghana) with a comparable HIV prevalence, 0.6 to 3.9
infective units per 10,000 donated units were found
[4]. A further limitation of this evaluation is that only
window-phase HIV transmissions are considered, dis-
regarding HIV transmission due to technical or human
failure which could also potentially be reduced by
additional screening tests [35]. Also, blood transfusion
utilization data in this study are obtained in urban
Accra at the Korle Bu Teaching Hospital, which may
not represent the situation in rural areas of Ghana.
The use of cost-effectiveness ratios to prioritize
funding of health-care interventions and to compare
them in different settings is increasing as an approach
but is not without controversy. Thresholds for regard-
ing interventions as cost-effective in low-income coun-
tries were suggested ranging from once the GNI per
capita up to three times the GNI per capita [9,10,14].
Screening blood donations on HIV-antibody was esti-
mated to be cost-saving and to gain DALYs and should
therefore always be implemented. Only if the costs
of additional screening techniques were reduced con-
siderably, would the corresponding cost-effectiveness
ratios fall below the GNI per capita thresholds.
ID-NAT screening could fall within the range of these
thresholds if price cuts on test kits, license fees, and
equipment results in reduced test costs per donation at
least to US$10.14.
Health-care interventions in sub-Saharan Africa tar-
geted at communicable diseases are associated with
cost-effectiveness ratios ranging from US$121 per
DALY averted for malaria control, US$310 per DALY
averted for prevention of mother-to-child HIV trans-
mission up to US$542 to 1280 per DALY averted or
US$1180 per life-year gained for providing HAART
[11,12,36]. Expanding blood donation screening with
HIV-antigen tests does not compare favorably to these
speciﬁc interventions. Compared to cost-effectiveness
ratios for expanding HIV screening in the more devel-
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oped world, which easily exceed US$1 million per
DALY averted, (incremental) cost-effectiveness ratios
found for introducing additional screening in Ghana
represent much greater value.
Our study shows that the current policy of HIV-
antibody screening of blood donations is saving costs
and provides health gains in Accra (Ghana), justifying
the broad implementation of this strategy. Currently,
introducing either MP-NAT or ID-NAT testing along-
side HIV-antibody screening cannot be regarded cost-
effective in Accra (Ghana). Reduction in test costs could
change this. Certainly, screening cost reductions could
bring p24-antigen screening within acceptable limits. It
is essential that implementing any additional screening
test should also include improvement in training of
personnel, simpliﬁcation and automation of adminis-
tration, and dispensing systems to reduce human and
technical failure. Equally important, blood banks
should move from solely testing donations or donors to
maintaining a low-risk regular voluntary donor pool
combined with an adequate follow-up of these donors
[37,38]. Furthermore, consolidation of blood banking
activities and steering by a national transfusion author-
ity is necessary to build technology and human resource
for implementing demanding screening techniques such
as NAT testing ever in the future.
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